Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002748 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma
A Phase 1 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT00002748 is a Phase 1 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 38 participants.
The verdict
NCT00002748, a Phase 1 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
RATIONALE: Inserting the gene for interleukin-2 into a person's neuroblastoma cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of using interleukin-2 gene-modified neuroblastoma cells in treating children who have refractory or recurrent neuroblastoma.
Interventions
- BIOLOGICAL interleukin-2 gene
- BIOLOGICAL gene-modified tumor cell vaccine therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 1991-12 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002748
The ClinicalTrials.gov registry entry for NCT00002748 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which interleukin-2 gene is the first listed.
NCT00002748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002748 about?
NCT00002748 is a clinical study titled "Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma". RATIONALE: Inserting the gene for interleukin-2 into a person's neuroblastoma cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of using interleukin-2 gene-modified neuroblastoma cells in treating children who have refractory or...
What is the current status of trial NCT00002748?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 1991-12. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00002748?
The interventions under investigation include: interleukin-2 gene (BIOLOGICAL), gene-modified tumor cell vaccine therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002748?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.